Compare LDI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | DBVT |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 954.8M | 769.4M |
| IPO Year | 2021 | N/A |
| Metric | LDI | DBVT |
|---|---|---|
| Price | $2.10 | $19.08 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.00 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 3.8M | 709.3K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,780,000.00 | $5,502,000.00 |
| Revenue This Year | $24.99 | $1,768.71 |
| Revenue Next Year | $18.02 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.74 | N/A |
| 52 Week Low | $1.01 | $2.99 |
| 52 Week High | $5.05 | $26.19 |
| Indicator | LDI | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 55.95 |
| Support Level | $2.02 | $18.78 |
| Resistance Level | $2.88 | $19.90 |
| Average True Range (ATR) | 0.12 | 1.39 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 11.18 | 18.19 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.